Plain-English translation of NCT00588185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tests whether two new imaging scans—using [18F]-Fluoro-2-Deoxy-D-Glucose and [18F] Dihydro-Testosterone—can better help doctors see where prostate cancer is spreading and whether treatment is working. These scans are designed to find areas of cancer activity in your body that standard imaging might miss, and to show how your cancer is responding to therapy.
Standard ways of tracking prostate cancer (like PSA blood tests and conventional imaging) don't always give doctors a complete picture of how the disease is progressing or responding to treatment. This trial exists to see whether these two new imaging approaches could provide earlier and more accurate information to guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would receive two specialized imaging scans at Memorial Sloan Kettering Cancer Center. During each scan, a small amount of radioactive tracer (the imaging medication) is injected into your bloodstream, and then a PET scanner takes pictures to show where cancer activity is occurring in your body. The study team will compare these images to your standard imaging scans and PSA results to see if the new scans provide better information about your cancer's progression.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States